Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma 6Glioma 6Glioblastoma 5Colorectal Neoplasms 5Pancreatic Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Melanoma 4Breast Neoplasms 4Sarcoma 3Prostatic Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Pancreatic Ductal Adenocarcinoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia 2Immunoglobulin Light-chain Amyloidosis 2Head and Neck Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Squamous Cell 2Carcinoma, Basal Cell 2Burkitt Lymphoma 2Brain Neoplasms 2Advanced Solid Tumors 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Smoking Cessation 1

Interventions

brivaracetam 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Epilepsy × 30 days × Clear all
NCT05029960 2026-06-03

Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas

University of Rochester

Phase EARLY_PHASE1 Terminated
3 enrolled
CNS

Brain Neoplasms, Epilepsy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡